Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hypersensitivity Reaction
  Free Subscription

Articles published in
Br J Dermatol
    April 2024
  1. SIMPSON EL, Eckert L, Gadkari A, Brown TM, et al
    Evaluating the clinical utility of the Atopic Dermatitis Control Tool: measurement properties and agreement between patients' responses and clinicians' impressions of atopic dermatitis control.
    Br J Dermatol. 2024 Apr 9:ljae056. doi: 10.1093.
    >> Share

    March 2024
  2. SANDER N, Stolzl D, Fonfara M, Hartmann J, et al
    Blockade of IL-13 signaling improves skin barrier function and biology in patients with moderate to severe atopic dermatitis.
    Br J Dermatol. 2024 Mar 26:ljae138. doi: 10.1093.
    >> Share

  3. BENTZ P, Weisshaar E
    Biomarkers as key concepts in managing atopic dermatitis and psoriasis: Unlocking new ways of care for patient suffering from chronic hand dermatoses.
    Br J Dermatol. 2024 Mar 26:ljae127. doi: 10.1093.
    >> Share


  4. Correction to: Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis.
    Br J Dermatol. 2024 Mar 22:ljae112. doi: 10.1093.
    >> Share


  5. The relationship between paediatric eczema and cognition.
    Br J Dermatol. 2024;190:e41.
    >> Share


  6. A guide to using the core outcome set for eczema.
    Br J Dermatol. 2024;190:e44.
    >> Share

  7. NIELSEN W, Drucker AM
    The need and benefit of the Harmonising Outcome Measures for Eczema user's guide.
    Br J Dermatol. 2024;190:462-463.
    >> Share


  8. Correction to: Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2024 Mar 12:ljae093. doi: 10.1093.
    >> Share

  9. CHEN GF, Xu S, White MA, Cohen JM, et al
    Association between atopic dermatitis and eating disorders: a cross-sectional study in the All of Us Research Program.
    Br J Dermatol. 2024 Mar 11:ljae103. doi: 10.1093.
    >> Share

    February 2024
  10. RAMESSUR R, Dand N, Langan SM, Saklatvala J, et al
    Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research- an inter-disciplinary perspective.
    Br J Dermatol. 2024 Feb 29:ljae080. doi: 10.1093.
    >> Share


  11. A clinical trial investigating if antibacterial therapeutic clothing could improve atopic dermatitis.
    Br J Dermatol. 2024;190:e29.
    >> Share

  12. BREHON A, Bensefa-Colas L, D'Andrea C, Jeziorski E, et al
    Guidelines for cold urticaria management established by the Centre of Evidence of Dermatology and the Urticaria Group of the French Society of Dermatology.
    Br J Dermatol. 2024;190:445-447.
    >> Share

  13. KOBYLETZKI LBV, Svensson A
    Long term outcome measures of atopic dermatitis gain importance: a validation study filling a research gap.
    Br J Dermatol. 2024 Feb 5:ljae049. doi: 10.1093.
    >> Share

    January 2024
  14. DAINTY KN, Thibau IJC, Amog K, Drucker AM, et al
    Towards a patient-centered definition for atopic dermatitis flare: A qualitative study among adults with atopic dermatitis.
    Br J Dermatol. 2024 Jan 30:ljae037. doi: 10.1093.
    >> Share


  15. Comparing systemic treatments for eczema.
    Br J Dermatol. 2024;190:e16.
    >> Share


  16. A study using machine learning to help identify subgroups of adults with atopic dermatitis.
    Br J Dermatol. 2024;190:e19.
    >> Share


  17. A decreasing trend of atopic dermatitis among children in Sweden.
    Br J Dermatol. 2024;190:e17.
    >> Share

  18. SOEGIHARTO R, Westmeijer M, Boekema-Bakker N, Groenewegen IAM, et al
    Prevalence of chronic urticaria and healthcare usage of patients with the condition in primary care: a population-based study in the Netherlands.
    Br J Dermatol. 2024;190:287-289.
    >> Share

  19. FUNCH AB, Glindvad Ahlstrom M, Johansen JD, Geisler C, et al
    Neutrophil Infiltration in Allergic Contact Dermatitis to Nickel.
    Br J Dermatol. 2024 Jan 4:ljad499. doi: 10.1093.
    >> Share

  20. YOO LJH, Stefanovic N, Watchorn RE
    Atopic Dermatitis and Autism: Tactile Hypersensitivity Impeding on Topical Therapy Use.
    Br J Dermatol. 2024 Jan 4:ljae005. doi: 10.1093.
    >> Share

  21. SMITH KA, Hiyoshi A, Vingeliene S, von Kobyletzki L, et al
    Atopic dermatitis and cognitive function: a sibling comparison study among males in Sweden.
    Br J Dermatol. 2024 Jan 3:ljae004. doi: 10.1093.
    >> Share

    December 2023
  22. JOHNSON C, Smith P, Haran K, Kranyak A, et al
    Comment on 'Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study'.
    Br J Dermatol. 2023 Dec 27:ljad529. doi: 10.1093.
    >> Share


  23. Nemolizumab reduces itch and improves other signs of atopic dermatitis in children aged 6-12 years.
    Br J Dermatol. 2023;190:e2.
    >> Share


  24. Greater understanding about differences in the long-term course of eczema and their risk factors in children.
    Br J Dermatol. 2023;190:e5.
    >> Share


  25. A study about how many people around the world have atopic dermatitis.
    Br J Dermatol. 2023;190:e6.
    >> Share


  26. The role of enhancers in eczema and psoriasis.
    Br J Dermatol. 2023;190:e1.
    >> Share

  27. TIERNEY E, Evans P, Broderick V, Wynn R, et al
    Successful response to dupilumab in a refractory case of atopic dermatitis-like chronic cutaneous graft-versus-host disease.
    Br J Dermatol. 2023 Dec 20:ljad526. doi: 10.1093.
    >> Share

  28. FORKEL S, Schubert S, Corvin L, Heine G, et al
    Contact allergies to dental materials in patients.
    Br J Dermatol. 2023 Dec 20:ljad525. doi: 10.1093.
    >> Share

  29. THOMAS KS, Howells L, Leshem YA, Simpson EL, et al
    How to use the HOME Core Outcome Set for atopic dermatitis trials - a users' guide.
    Br J Dermatol. 2023 Dec 20:ljad497. doi: 10.1093.
    >> Share

  30. ABDI P, Haq Z, Diaz MJ, Maibach HI, et al
    Infectious disease among adults with allergic contact dermatitis: A propensity score-matched case-control study.
    Br J Dermatol. 2023 Dec 19:ljad504. doi: 10.1093.
    >> Share

  31. SOCKLER PG, Hooper SR, Abuabara K, Ma EZ, et al
    Atopic dermatitis, cognitive function, and psychiatric comorbidities across early childhood and adolescence in a population-based UK birth cohort.
    Br J Dermatol. 2023 Dec 7:ljad486. doi: 10.1093.
    >> Share

  32. WEIDINGER S, Simpson EL, Silverberg JI, Barbarot S, et al
    Burden of Atopic Dermatitis in Pediatric Patients: An International Cross-sectional Study.
    Br J Dermatol. 2023 Dec 4:ljad449. doi: 10.1093.
    >> Share

    November 2023
  33. YU J
    Are perinatal antibiotics responsible for atopic dermatitis? The Debate Rages On.
    Br J Dermatol. 2023 Nov 30:ljad477. doi: 10.1093.
    >> Share

  34. KIM M, Choi Y, Lee M, Kang J, et al
    Maternal SARS-CoV-2 infection during pregnancy and subsequent risk of atopic dermatitis in offspring: a nationwide birth cohort study in South Korea.
    Br J Dermatol. 2023 Nov 30:ljad478. doi: 10.1093.
    >> Share

  35. CAZZANIGA S, Simon D
    Decoding Atopic Dermatitis: Unveiling Phenotypes Through Data-Driven Methods.
    Br J Dermatol. 2023 Nov 17:ljad453. doi: 10.1093.
    >> Share


  36. Correction to: Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial.
    Br J Dermatol. 2023 Nov 16:ljad442. doi: 10.1093.
    >> Share


  37. Improved sleep in adults with atopic dermatitis using the treatment dupilumab.
    Br J Dermatol. 2023;189:e106.
    >> Share


  38. A clinical trial in children and young people with severe eczema comparing methotrexate with ciclosporin.
    Br J Dermatol. 2023;189:e105.
    >> Share


  39. A study about the presence of Staphylococcus aureus growth at birth and at 2 months of age in children who developed atopic dermatitis in the first 2 years of life.
    Br J Dermatol. 2023;189:e107.
    >> Share

  40. CHERREZ-OJEDA I, Thomsen SF, Gimenez-Arnau A
    Alexithymia prevalence in individuals with chronic urticaria and its association with illness severity and therapeutic profile.
    Br J Dermatol. 2023;189:766-767.
    >> Share

  41. WAN J
    Changes in the epidemiology of atopic dermatitis: putting them into context.
    Br J Dermatol. 2023 Nov 11:ljad443. doi: 10.1093.
    >> Share

  42. YOSIPOVITCH G, Lio PA, Rosmarin D, Serra-Baldrich E, et al
    Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials.
    Br J Dermatol. 2023 Nov 6:ljad435. doi: 10.1093.
    >> Share

  43. RAGAMIN A, Schappin R, de Graaf M, Tupker RA, et al
    The effectiveness of antibacterial therapeutic clothing compared with non-antibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: A randomized controlled, observer-blind pragmatic trial (ABC trial).
    Br J Dermatol. 2023 Nov 4:ljad437. doi: 10.1093.
    >> Share

  44. SHIMON SV, Desai K, Miteva M, Nadji M, et al
    High Expression of Interleukin-17A in Cutaneous Sarcoidosis.
    Br J Dermatol. 2023 Nov 4:ljad438. doi: 10.1093.
    >> Share

  45. HAIDER S, Granell R, Curtin JA, Holloway JW, et al
    Identification of eczema clusters and their association with filaggrin and atopic comorbidities: analysis of five birth cohorts.
    Br J Dermatol. 2023 Nov 3:ljad326. doi: 10.1093.
    >> Share

    October 2023
  46. CHIESA FUXENCH Z, Mitra N, Del Pozo D, Hoffstad O, et al
    In utero or early in life exposure to antibiotics and the risk of childhood atopic dermatitis, a population-based cohort study.
    Br J Dermatol. 2023 Oct 28:ljad428. doi: 10.1093.
    >> Share


  47. Lifetime burden of Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Br J Dermatol. 2023;189:e92.
    >> Share


  48. Safety and effectiveness of amlitelimab, a potential new treatment for atopic dermatitis: results of a clinical trial.
    Br J Dermatol. 2023;189:e90.
    >> Share


  49. Greater understanding about interpreting the Recap of atopic eczema (RECAP) questionnaire.
    Br J Dermatol. 2023;189:e95.
    >> Share

  50. OFENLOCH RF
    Filling the gap: investigating the interpretability of the Recap of atopic eczema questionnaire.
    Br J Dermatol. 2023;189:506-507.
    >> Share

  51. INGEN-HOUSZ-ORO S
    Epidermal necrolysis: a chronic disease associated with loss-of-life expectancy and lifetime healthcare expenditure.
    Br J Dermatol. 2023;189:505-506.
    >> Share

  52. LIU Y, Li Q, Chu C, Zhou Y, et al
    Insights into Stevens-Johnson syndrome/toxic epidermal necrolysis lifetime burden: assessing life expectancy, healthcare costs and quality of life.
    Br J Dermatol. 2023;189:648.
    >> Share

  53. ZHANG J, Ragamin A, Romeijn GLE, Loman L, et al
    Validity, reliability, responsiveness and interpretability of the Recap of atopic eczema (RECAP) questionnaire.
    Br J Dermatol. 2023;189:578-587.
    >> Share

  54. WELFRINGER-MORIN A, Bataille P, Drummond D, Bellon N, et al
    Comparison of idiopathic and drug-induced epidermal necrolysis in children.
    Br J Dermatol. 2023;189:631-633.
    >> Share

  55. NYMAND L, Nielsen ML, Vittrup I, Halling AS, et al
    Atopic dermatitis phenotypes based on cluster analysis of the Danish Skin Cohort.
    Br J Dermatol. 2023 Oct 18:ljad401. doi: 10.1093.
    >> Share

  56. DRUCKER AM, Lam M, Elsawi R, Prieto-Merino D, et al
    Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis.
    Br J Dermatol. 2023 Oct 13:ljad393. doi: 10.1093.
    >> Share

    September 2023
  57. AF KLINTEBERG M, Winberg A, Andersson M, Ronmark E, et al
    Decreasing prevalence of atopic dermatitis among Swedish schoolchildren. Three repeated population-based surveys.
    Br J Dermatol. 2023 Sep 30:ljad370. doi: 10.1093.
    >> Share


  58. Correction to: TMEM232 promotes the inflammatory response in atopic dermatitis via the nuclear factor-kappaB and signal transducer and activator of transcription 3 signalling pathways.
    Br J Dermatol. 2023 Sep 23:ljad346. doi: 10.1093.
    >> Share

  59. FLOHR C, Rosala-Hallas A, Jones AP, Beattie P, et al
    Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre, parallel group, assessor-blinded clinical trial.
    Br J Dermatol. 2023 Sep 19:ljad281. doi: 10.1093.
    >> Share

  60. NAKAHARA T, Fujita H, Tajima Y, Arima K, et al
    Evaluating the usefulness of the Atopic Dermatitis Control Tool for assessing disease control among individuals with atopic dermatitis in Japan.
    Br J Dermatol. 2023 Sep 15:ljad344. doi: 10.1093.
    >> Share


  61. The risk of deep-vein blood clots in people with atopic dermatitis (eczema).
    Br J Dermatol. 2023;189:e75.
    >> Share


  62. A review of major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors.
    Br J Dermatol. 2023;189:e69.
    >> Share

  63. VOORBERG AN, Kamphuis E, Christoffers WA, Schuttelaar MLA, et al
    Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.
    Br J Dermatol. 2023;189:400-409.
    >> Share

  64. TIAN J, Zhang D, Yang Y, Huang Y, et al
    The global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study.
    Br J Dermatol. 2023 Sep 14:ljad339. doi: 10.1093.
    >> Share

  65. FUXENCH ZCC, Wan J, Wang S, Syed MN, et al
    Atopic Dermatitis and risk for headache disorders and migraines: a population-based cohort study in children and adults from the United Kingdom.
    Br J Dermatol. 2023 Sep 6:ljad325. doi: 10.1093.
    >> Share

  66. LLOYD-LAVERY A
    Nemolizumab to target the itch-scratch cycle in paediatric atopic dermatitis.
    Br J Dermatol. 2023 Sep 2:ljad319. doi: 10.1093.
    >> Share

  67. SUI JY, Eichenfield DZ, Sun BK
    The Role of Enhancers in Psoriasis and Atopic Dermatitis.
    Br J Dermatol. 2023 Sep 2:ljad321. doi: 10.1093.
    >> Share

  68. LEE EY, Drucker AM
    A detailed evaluation of dupilumab's effect on sleep in adults with atopic dermatitis.
    Br J Dermatol. 2023 Sep 2:ljad320. doi: 10.1093.
    >> Share

    August 2023

  69. The impact of a dose reduction of dupilumab when treating people with well-controlled atopic dermatitis.
    Br J Dermatol. 2023;189:e68.
    >> Share

  70. ROESNER LM, Wittmann M
    Hand eczema leaves systemic traces.
    Br J Dermatol. 2023;189:e56-e59.
    >> Share

  71. ARENTS BWM, van Zuuren EJ, Hughes O, Fedorowicz Z, et al
    The future is now: the Global Atopic Dermatitis Atlas (GADA).
    Br J Dermatol. 2023 Aug 11:ljad286. doi: 10.1093.
    >> Share

  72. MEROLA JF, Chiou AS, During E, Costanzo A, et al
    Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase 4 randomized double-blinded placebo-controlled DUPISTAD study.
    Br J Dermatol. 2023 Aug 10:ljad284. doi: 10.1093.
    >> Share

    July 2023
  73. IGARASHI A, Katsunuma T, Matsumura T, Komazaki H, et al
    Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: Results from a phase III, randomised, double-blind, placebo-controlled, multicentre study.
    Br J Dermatol. 2023 Jul 31:ljad268. doi: 10.1093.
    >> Share

  74. RINNOV MR, Gerner T, Halling AS, Liljendahl MS, et al
    The association between S. aureus colonization on cheek skin at 2 months and subsequent atopic dermatitis in a prospective birth cohort.
    Br J Dermatol. 2023 Jul 22:ljad249. doi: 10.1093.
    >> Share

  75. WEIDINGER S, Bieber T, Cork MJ, Reich A, et al
    Safety and efficacy of amlitelimab, a fully human, non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomised placebo-controlled trial.
    Br J Dermatol. 2023 Jul 18:ljad240. doi: 10.1093.
    >> Share


  76. Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis.
    Br J Dermatol. 2023;189:e39.
    >> Share

  77. LAM M, Spuls PI, Leshem YA, Gerbens LAA, et al
    Reporting of Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set Instruments in randomized clinical trials for systemic treatments in Atopic Dermatitis.
    Br J Dermatol. 2023 Jul 12:ljad237. doi: 10.1093.
    >> Share

  78. CHIU YM, Chiu HY
    Lifetime risk, life expectancy, loss-of-life expectancy, and lifetime healthcare expenditure for Stevens-Johnson syndrome/toxic epidermal necrolysis in Taiwan: follow-up of a nationwide cohort from 2008 to 2019.
    Br J Dermatol. 2023 Jul 10:ljad234. doi: 10.1093.
    >> Share


  79. Better understand about circulating biomarkers and disease severity of chronic hand eczema and atopic dermatitis.
    Br J Dermatol. 2023;189:e34.
    >> Share

  80. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2023;189:53-61.
    >> Share

  81. WARREN RB, Basey V, Lynam A, Curtis C, et al
    The risk of venous thromboembolism in atopic dermatitis: A matched cohort analysis in UK primary care.
    Br J Dermatol. 2023 Jul 7:ljad212. doi: 10.1093.
    >> Share

  82. CONNOLLY A, Walsh S, Philippidou M, Salisbury J, et al
    Acute hepatic failure in trimethoprim-induced drug rash with eosinophilia and systemic symptoms (DRESS).
    Br J Dermatol. 2023;189:140-141.
    >> Share

  83. ERTUS C, Scailteux LM, Lescoat A, Berthe P, et al
    Major adverse cardiovascular events in patients treated with oral Janus kinase inhibitors for atopic dermatitis: a systematic review and meta-analysis.
    Br J Dermatol. 2023 Jul 6:ljad229. doi: 10.1093.
    >> Share

  84. OLLECH A, Lefferdink R, Sheth A, Blumstein A, et al
    Systemic Immunosuppressive Therapies for Children with Refractory Atopic Dermatitis: A Large Real-Life Cohort Study.
    Br J Dermatol. 2023 Jul 5:ljad222. doi: 10.1093.
    >> Share

  85. HONG CH, Lee CH
    A nationwide UK cohort study reveals an association between atopic dermatitis and venous thromboembolism.
    Br J Dermatol. 2023 Jul 5:ljad221. doi: 10.1093.
    >> Share

    June 2023
  86. RUTH E, Heraghty F, Flynn N, McGlynn T, et al
    No evidence of isotretinoin sensitisation in peanut allergic children - a cross-sectional study.
    Br J Dermatol. 2023 Jun 28:ljad214. doi: 10.1093.
    >> Share

  87. LUO M, Zhu C, Lin J, Lin L, et al
    Bidirectional Mendelian randomization analysis did not indicate a causal relationship between atopic dermatitis and COVID-19.
    Br J Dermatol. 2023 Jun 27:ljad208. doi: 10.1093.
    >> Share

  88. OGAWA-MOMOHARA M, Muro Y, Murase C, Taki T, et al
    Allergen-specific IgG4 increase in atopic dermatitis with long-term dupilumab use.
    Br J Dermatol. 2023 Jun 27:ljad207. doi: 10.1093.
    >> Share

  89. HAN JH, Ju HJ, Kang H, Lee JH, et al
    Autoimmune, Inflammatory, Allergic, and Neuropsychiatric Outcomes of Offspring Born to Mothers with Vitiligo: A Nationwide Population-based Birth Cohort Study of Korea.
    Br J Dermatol. 2023 Jun 19:ljad196. doi: 10.1093.
    >> Share

    May 2023

  90. Results from 1 year of treatment with lebrikizumab for atopic dermatitis.
    Br J Dermatol. 2023;188:e43.
    >> Share


  91. Atopic eczema: palmar patterns associated with filaggrin variants, disease severity and barrier function in a South Asian population.
    Br J Dermatol. 2023;188:e46.
    >> Share


  92. Atopic dermatitis across the globe: differences in prevalence and access to treatments.
    Br J Dermatol. 2023;188:e42.
    >> Share

  93. THOMAS BR, Tan XL, Van Duijvenboden S, Hogan SC, et al
    Deep palmar phenotyping in atopic eczema: patterns associated with filaggrin variants, disease severity and barrier function in a South Asian population.
    Br J Dermatol. 2023;188:785-792.
    >> Share

  94. HIJNEN D, Olydam J
    Prediction of response to dupilumab treatment.
    Br J Dermatol. 2023;188:e41.
    >> Share


  95. Correction to: 319 Effects of omega-3 fatty acid supplementation on atopic dermatitis.
    Br J Dermatol. 2023 May 22:ljad154. doi: 10.1093.
    >> Share

  96. SPEKHORST LS, Boesjes CM, Loman L, Zuithoff NPA, et al
    Successful tapering of dupilumab in atopic dermatitis patients with low disease activity: a large pragmatic daily practice study from the BioDay registry.
    Br J Dermatol. 2023 May 13:ljad159. doi: 10.1093.
    >> Share

    April 2023
  97. FLOHR C, Irvine AD, Cork MJ, Simpson EL, et al
    Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6-11 years with severe atopic dermatitis.
    Br J Dermatol. 2023 Apr 30:ljad124. doi: 10.1093.
    >> Share

  98. ARENTS BWM
    Intriguing findings on lebrikizumab for treating moderate-to-severe atopic dermatitis.
    Br J Dermatol. 2023 Apr 24:ljad068. doi: 10.1093.
    >> Share


  99. Serum biomarker analysis to identify subtypes of atopic dermatitis in China and to help with predicting the effectiveness of treatment with dupilumab.
    Br J Dermatol. 2023;188:e37.
    >> Share

  100. BEN ABDALLAH H, Johansen C
    Transmembrane protein 232 (TMEM232) regulates inflammation in experimental models of atopic dermatitis.
    Br J Dermatol. 2023 Apr 17:ljad127. doi: 10.1093.
    >> Share

  101. QUAADE AS, Wang X, Solberg JBK, Ulrich NH, et al
    Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis.
    Br J Dermatol. 2023 Apr 13:ljad110. doi: 10.1093.
    >> Share

  102. VITTRUP I
    Malignancy risk in atopic dermatitis: heterogenous effects and perspectives.
    Br J Dermatol. 2023 Apr 11:ljad119. doi: 10.1093.
    >> Share

    March 2023
  103. TORRELO A, Rewerska B, Galimberti M, Paller A, et al
    Efficacy and safety of baricitinib in combination with topical corticosteroids in pediatric patients with moderate-to-severe atopic dermatitis with inadequate response to topical corticosteroids: results from a phase 3, randomized, double-blind, place
    Br J Dermatol. 2023 Mar 31:ljad096. doi: 10.1093.
    >> Share

  104. BLAUVELT A, Thyssen JP, Guttman-Yassky E, Bieber T, et al
    Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
    Br J Dermatol. 2023 Mar 30:ljad022. doi: 10.1093.
    >> Share


  105. Factors associated with mental illness in adults with atopic eczema or psoriasis.
    Br J Dermatol. 2023;188:e27.
    >> Share


  106. Quality of life of Bangladeshi children and young adults with atopic eczema and their families in East London.
    Br J Dermatol. 2023;188:e33.
    >> Share

  107. TAWFIK SS, Thomas BR, Kelsell DP, Grigg J, et al
    Dermatology Quality of Life Index scores in Bangladeshi patients with atopic eczema and their families in East London.
    Br J Dermatol. 2023;188:524-532.
    >> Share

  108. MAGIN P, Fisher K
    Online behavioural interventions for children and young people with atopic eczema: refining the way forward.
    Br J Dermatol. 2023;188:453.
    >> Share

  109. VANCE TM, Li T, Cho E, Drucker AM, et al
    Prenatal antibiotic use and subsequent risk of atopic eczema.
    Br J Dermatol. 2023;188:561-563.
    >> Share

  110. CAPOZZA K
    Lost in translation: understanding the experience of atopic eczema among non-English-speaking families.
    Br J Dermatol. 2023;188:456-457.
    >> Share

  111. SINIKUMPU SP, Jokelainen J, Huilaja L
    The association between atopic dermatitis and acne: a retrospective Finnish nationwide registry study.
    Br J Dermatol. 2023 Mar 22:ljad086. doi: 10.1093.
    >> Share

  112. RAGAMIN A, Tupker RA, de Graaf M, Rustemeyer T, et al
    Investigator Global Assessment for impetiginization in Atopic Dermatitis (IGA impetiginization): Development and initial reliability testing.
    Br J Dermatol. 2023 Mar 22:ljad085. doi: 10.1093.
    >> Share

  113. PATHMARAJAH P, Corso R, Salam A, Shah G, et al
    Neutropenia in patients on dupilumab for atopic dermatitis: a case series and review of trial data.
    Br J Dermatol. 2023 Mar 17:ljad038. doi: 10.1093.
    >> Share

  114. HAN J, Cai X, Qin S, Zhang Z, et al
    TMEM232 Promotes the Inflammatory Response in Atopic Dermatitis via NF-kappaB and STAT3 Signaling Pathways.
    Br J Dermatol. 2023 Mar 17:ljad078. doi: 10.1093.
    >> Share

  115. MOSAM A, Todd G
    Global epidemiology and disparities in atopic dermatitis.
    Br J Dermatol. 2023 Mar 7:ljad042. doi: 10.1093.
    >> Share

  116. DRUCKER AM
    Atopic dermatitis in 2023 and beyond.
    Br J Dermatol. 2023 Mar 2:ljad053. doi: 10.1093.
    >> Share

    February 2023

  117. Atopic dermatitis and school performance in children and young adults.
    Br J Dermatol. 2023;188:e21.
    >> Share

  118. SUN X, Sheng A, Xu AE
    Successful treatment of vitiligo with crisaborole ointment: a report of two cases.
    Br J Dermatol. 2023;188:436-437.
    >> Share

  119. VON KOBYLETZKI L
    Which patients with atopic eczema and psoriasis develop depression, anxiety, and severe mental illness: is the evidence clear?
    Br J Dermatol. 2023 Feb 15:ljad009. doi: 10.1093.
    >> Share


  120. Small particles of cobalt cause eczema in people with allergies.
    Br J Dermatol. 2023;188:e20.
    >> Share


  121. Patients successfully treated with baricitinib for atopic dermatitis: what happens if they lower their dose or stop treatment?
    Br J Dermatol. 2023;188:e14.
    >> Share

  122. REICH K, Simpson E, Wollenberg A, Bissonnette R, et al
    Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.
    Br J Dermatol. 2023;188:208-217.
    >> Share

  123. GILL K, Xu J, Kozera E, Stewart T, et al
    Strongyloides screening prior to dupilumab therapy in atopic dermatitis: a retrospective cohort study evaluating screening utility.
    Br J Dermatol. 2023;188:294-295.
    >> Share

  124. SYMANZIK C, John SM
    Occupational exposure to cobalt nanoparticles: potential implications on risk assessment and preventive measures.
    Br J Dermatol. 2023;188:161-162.
    >> Share

  125. WU Y, Gu C, Wang S, Yin H, et al
    Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab.
    Br J Dermatol. 2023 Feb 9:ljad032. doi: 10.1093.
    >> Share

    January 2023
  126. MCSWEENEY SM, Bintcliffe K, Fassihi H, Sarkany R, et al
    Local cutaneous refractoriness to sun exposure following omalizumab injections in solar urticaria.
    Br J Dermatol. 2023 Jan 27:ljad012. doi: 10.1093.
    >> Share

  127. SIMPSON RC
    Safety of tralokinumab in atopic dermatitis.
    Br J Dermatol. 2023 Jan 26:ljad007. doi: 10.1093.
    >> Share

  128. KOGAME T, Yonekura S, Lovato P, Hirata M, et al
    Interleukin-13 inhibition by tralokinumab reduces inducible T-cell costimulator-positive innate lymphoid cells in skin lesions of atopic dermatitis.
    Br J Dermatol. 2023;188:146-148.
    >> Share

  129. ZHANG J, Schuttelaar MLA
    Water and adult eczema: the hard truth?
    Br J Dermatol. 2023;188:e1.
    >> Share

  130. VINCENT R, Ormerod E, Gollins CE, Rai N, et al
    Semi-virtual patch testing: the future?
    Br J Dermatol. 2023;188:137-139.
    >> Share

  131. ARDERN-JONES MR, Buchanan EE, Njungu S, O'Driscoll D, et al
    Successful Dose Reduction of Dupilumab in Atopic Dermatitis.
    Br J Dermatol. 2023 Jan 20:ljad011. doi: 10.1093.
    >> Share

  132. YEW YW, Apfelbacher CJ
    Validation of novel diagnostic criteria for atopic dermatitis in an adult and elderly Chinese population.
    Br J Dermatol. 2023 Jan 5:ljac143. doi: 10.1093.
    >> Share

    December 2022
  133. ADESANYA EI, Matthewman J, Schonmann Y, Hayes JF, et al
    Factors associated with depression, anxiety and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis.
    Br J Dermatol. 2022 Dec 19:ljac132. doi: 10.1093.
    >> Share

  134. YUE W, Cheng D, Sun Z, Shen Y, et al
    Validation of diagnostic criteria for atopic dermatitis and proposal of novel diagnostic criteria for adult and elderly Chinese populations: a multicentre, prospective, clinical setting-based study.
    Br J Dermatol. 2022 Dec 12:ljac097. doi: 10.1093.
    >> Share

  135. FLOHR C
    How we treat atopic dermatitis now and how that will change over the next 5 years.
    Br J Dermatol. 2022 Dec 7:ljac116. doi: 10.1093.
    >> Share

  136. GABES M, Ragamin A, Baker A, Kann G, et al
    Content validity of the Recap of atopic eczema (RECAP) instrument in Dutch, English and German to measure eczema control in young people with atopic eczema: a cognitive interview study.
    Br J Dermatol. 2022;187:919-926.
    >> Share

    November 2022
  137. HU C, Jansen PW
    Do adolescents with atopic dermatitis have lower cognitive function and school performance than their peers without atopic dermatitis?
    Br J Dermatol. 2022 Nov 29:ljac105. doi: 10.1093.
    >> Share

  138. ABUABARA K, Langan SM
    Atopic dermatitis across the life course.
    Br J Dermatol. 2022 Nov 18:ljac072. doi: 10.1093.
    >> Share

  139. TRIER AM, Kim BS
    Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies.
    Br J Dermatol. 2022 Nov 18:ljac016. doi: 10.1093.
    >> Share

  140. WEISSHAAR E, Bentz P, Haufe E, Heinrich L, et al
    Itching and treatments in atopic dermatitis (AD): results from the German AD registry TREATgermany.
    Br J Dermatol. 2022 Nov 17:ljac070. doi: 10.1093.
    >> Share

  141. CLAYTON K, Holbrook DJ, Vallejo A, Porter G, et al
    Skin programming of inflammatory responses to Staphylococcus aureus is compartmentalized according to epidermal keratinocyte differentiation status.
    Br J Dermatol. 2022 Nov 17:ljac088. doi: 10.1093.
    >> Share

  142. VITTRUP I, Andersen YMF, Skov L, Wu JJ, et al
    The association between atopic dermatitis, cognitive function and school performance in children and young adults.
    Br J Dermatol. 2022 Nov 3:ljac058. doi: 10.1093.
    >> Share

  143. ORCHARD D
    Preventing atopic eczema: vitamin D supplementation another piece of the puzzle?
    Br J Dermatol. 2022;187:630-631.
    >> Share

  144. EL-HEIS S, D'Angelo S, Curtis EM, Healy E, et al
    Maternal antenatal vitamin D supplementation and offspring risk of atopic eczema in the first 4 years of life: evidence from a randomized controlled trial.
    Br J Dermatol. 2022;187:659-666.
    >> Share

    October 2022
  145. MIDANDER K, Werner P, Isaksson M, Wisgrill L, et al
    Cobalt nanoparticles cause allergic contact dermatitis in humans.
    Br J Dermatol. 2022 Oct 28:ljac043. doi: 10.1093.
    >> Share

  146. TURNER CT, Zeglinski MR, Boivin W, Zhao H, et al
    Granzyme K contributes to endothelial microvascular damage and leakage during skin inflammation.
    Br J Dermatol. 2022 Oct 23:ljac017. doi: 10.1093.
    >> Share

  147. CUCKA B, Biglione B, Zhou L, Phillips EJ, et al
    Drug reaction with eosinophilia and systemic symptoms in patients hospitalized with COVID-19: a case series from a large US healthcare system.
    Br J Dermatol. 2022;187:619-622.
    >> Share

    September 2022
  148. SIMPSON EL, Merola JF, Silverberg JI, Reich K, et al
    Safety of Tralokinumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Pooled Analysis of Five Randomized, Double-blind, Placebo-controlled Phase 2 and Phase 3 Trials.
    Br J Dermatol. 2022 Sep 9. doi: 10.1111/bjd.21867.
    >> Share

  149. KIM RW, Barta K, Begolka WS, Capozza K, et al
    The quantitative impact of atopic dermatitis on caregivers across multiple life domains.
    Br J Dermatol. 2022 Sep 3. doi: 10.1111/bjd.21855.
    >> Share


  150. Revolutionizing Atopic Dermatitis, 9-11 April 2022.
    Br J Dermatol. 2022;187:e80-e155.
    >> Share

    August 2022
  151. LANDIS MN, Arya M, Smith S, Draelos Z, et al
    Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomised, double-blind, vehicle-controlled, dose-ranging, and parallel-group study.
    Br J Dermatol. 2022 Aug 20. doi: 10.1111/bjd.21826.
    >> Share

  152. KIM RW, Barta K, Begolka WS, Capozza K, et al
    Qualitative analysis of the impact of atopic dermatitis on caregivers and the quantitative impact of atopic dermatitis on caregivers across multiple life domains.
    Br J Dermatol. 2022 Aug 16. doi: 10.1111/bjd.21828.
    >> Share

  153. CHRISTIANSEN AG, Carstensen O, Sommerlund M, Clausen PA, et al
    Prevalence of skin sensitisation and dermatitis among epoxy-exposed workers in the wind turbine industry.
    Br J Dermatol. 2022 Aug 16. doi: 10.1111/bjd.21830.
    >> Share

  154. MORGAN CL, Thomas M, Stander S, Jabbar-Lopez ZK, et al
    Epidemiology of prurigo nodularis in England: a retrospective database analysis.
    Br J Dermatol. 2022;187:188-195.
    >> Share

    July 2022
  155. YANG N, Chen L, Shao J, Jiang F, et al
    Dupilumab with concomitant JAK inhibitor: A novel treatment strategy for atopic dermatitis with poor response to dupilumab.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21776.
    >> Share

  156. WORM M, Thyssen JP, Schliemann S, Bauer A, et al
    The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
    Br J Dermatol. 2022;187:42-51.
    >> Share

    June 2022
  157. SCHNEEWEISS MC, Kirchgesner J, Wyss R, Jin Y, et al
    Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study.
    Br J Dermatol. 2022 Jun 19. doi: 10.1111/bjd.21704.
    >> Share

  158. BETTUZZI T, Hua C, Diaz E, Colin A, et al
    Epidermal necrolysis: characterization of different phenotypes using an unsupervised clustering analysis.
    Br J Dermatol. 2022;186:1037-1039.
    >> Share

    May 2022
  159. CHEN CW, Wei JC
    Response to 'Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th Revision codes'.
    Br J Dermatol. 2022;186:910-911.
    >> Share

  160. GOLDENBERG M, Krishna SG, Milani-Nejad N, Trinidad JC, et al
    Response to: 'Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9(th) and 10(th) Revision codes': reply from the authors.
    Br J Dermatol. 2022;186:911.
    >> Share

    April 2022
  161. BIEBER T, Reich K, Paul C, Tsunemi Y, et al
    Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response, Intolerance, or Contraindication to Cyclosporine: Results From a Randomized, Placebo-Control
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21630.
    >> Share

  162. LAQUER V, Parra V, Lacour JP, Takahashi H, et al
    IL-33 antibody failed to demonstrate benefit in a phase 2 double-blind, randomised placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21631.
    >> Share

  163. JENDOUBI F, Shourik J, Seneschal J, Giordano-Labadie F, et al
    Longer Dupilumab Dosing Intervals in Adult Patients with Atopic Dermatitis: Experience from a French Multicentre Retrospective Cohort Study.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21628.
    >> Share

  164. SIMPSON EL, Bissonnette R, Paller AS, King B, et al
    The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): A Clinical Outcome Measure for the Severity of Atopic Dermatitis.
    Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21615.
    >> Share


  165. Revolutionizing Atopic Dermatitis, 11-13 December 2021.
    Br J Dermatol. 2022;186:e135-e185.
    >> Share

  166. BARBAROT S
    Targeting the itch-scratch vicious circle in atopic eczema.
    Br J Dermatol. 2022;186:608.
    >> Share

    March 2022
  167. JACOBY TV, Otto TS, Asdourian MS, Shah N, et al
    Association of preexisting drug allergies with cutaneous immune related adverse events among patients on immune checkpoint inhibitor therapy.
    Br J Dermatol. 2022 Mar 15. doi: 10.1111/bjd.21243.
    >> Share

  168. NOVAK N, Cabanillas B
    Herpesvirus, serious and opportunistic infections associated with atopic dermatitis.
    Br J Dermatol. 2022 Mar 6. doi: 10.1111/bjd.20982.
    >> Share

  169. SABROE RA, Lawlor F, Grattan CEH, Ardern-Jones MR, et al
    British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021.
    Br J Dermatol. 2022;186:398-413.
    >> Share

  170. GOLDENBERG M, Amigo M, Krishna SG, Milani-Nejad N, et al
    Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th Revision codes.
    Br J Dermatol. 2022;186:583-585.
    >> Share

    February 2022
  171. NGUYEN R
    Ocular conjunctivitis in biological therapies for atopic dermatitis.
    Br J Dermatol. 2022 Feb 16. doi: 10.1111/bjd.20945.
    >> Share

  172. FUTAMURA M
    Easy assessment tool for disease severity of atopic dermatitis in clinical practice.
    Br J Dermatol. 2022 Feb 6. doi: 10.1111/bjd.20951.
    >> Share

  173. MARGOLIS DJ
    Atopic dermatitis: filaggrin and skin barrier dysfunction.
    Br J Dermatol. 2022 Feb 6. doi: 10.1111/bjd.20946.
    >> Share

  174. GLEESON D, Cliff S, Das M
    Eruptive keratoacanthomas associated with dupilumab therapy.
    Br J Dermatol. 2022;186:376-377.
    >> Share

  175. GAUDIN O, Milpied B, Papouin B, Hue S, et al
    Lupus erythematosus and epidermal necrolysis: a case series of 16 patients.
    Br J Dermatol. 2022;186:372-374.
    >> Share

    January 2022
  176. PAKHCHANIAN H, Raiker R, Wolf M, Trotter SC, et al
    Examining the Risk of Breakthrough Infection and COVID-19 Vaccination Safety in Atopic Dermatitis Patients.
    Br J Dermatol. 2022 Jan 27. doi: 10.1111/bjd.21038.
    >> Share

  177. PENNY CL, Quow K, Rundle CW, Al-Rohil RN, et al
    Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
    Br J Dermatol. 2022 Jan 19. doi: 10.1111/bjd.21022.
    >> Share

  178. EBATA T
    Dose flexibility of oral Janus kinase inhibitors for long-term control of atopic dermatitis.
    Br J Dermatol. 2022 Jan 19:ljac082. doi: 10.1093.
    >> Share

  179. YOSIPOVITCH G, Papp K, Forman S, Han G, et al
    The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase 3 trials.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21015.
    >> Share

  180. KOZERA E, Stewart T, Gill K, De La Vega MA, et al
    Dupilumab Associated Head and Neck Dermatitis is Associated with Elevated Pre-Treatment Serum Malassezia-Specific Immunoglobulin E: A Multicenter, Prospective Cohort Study.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21019.
    >> Share

  181. KEZIC S, McAleer MA, Jakasa I, Goorden SMI, et al
    Children with atopic dermatitis show increased activity of beta- glucocerebrosidase and stratum corneum levels of glucosylcholesterol that are strongly related to local cytokine milieu.
    Br J Dermatol. 2022 Jan 7. doi: 10.1111/bjd.20979.
    >> Share

  182. ARENTS BWM, Zuuren EJV, Vermeulen S, Schoones JW, et al
    Global Guidelines in Dermatology Mapping Project (GUIDEMAP) - a systematic review of atopic dermatitis clinical practice guidelines: are they clear, unbiased, trustworthy and evidence based (CUTE)?
    Br J Dermatol. 2022 Jan 4. doi: 10.1111/bjd.20972.
    >> Share

    November 2021
  183. SINIKUMPU SP, Huilaja L
    Challenges of multidimensional atopic dermatitis.
    Br J Dermatol. 2021 Nov 24. doi: 10.1111/bjd.20874.
    >> Share

  184. DEZOTEUX F, El Mesbahi S, Tedbirt B, Grosjean J, et al
    Immunomodulatory or/and immunosuppressive drugs should not avoid skin test for the assessment of drug allergy.
    Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20901.
    >> Share

  185. MARNIQUET ME, Seneschal J, Darrigade AS, Staumont-Salle D, et al
    Reasons for Discontinuation of dupilumab in Adult Atopic Dermatitis in Clinical Practice.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20883.
    >> Share

  186. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Risk of herpesvirus, serious, and opportunistic infections in atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20887.
    >> Share

  187. CHIESA Z
    How important is it to distinguish between eczema and atopic dermatitis in infants? Implications for prognosis and epidemiological research.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20814.
    >> Share

  188. BEN ABDALLAH H, Vestergaard C
    Atopic dermatitis, hypertension and cardiovascular disease.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20802.
    >> Share

  189. PALLER AS, Tan JKL, Bagel J, Rossi AB, et al
    IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20872.
    >> Share

  190. KABASHIMA K, Matsumura T, Komazaki H, Kawashima M, et al
    Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20873.
    >> Share

    October 2021
  191. HOYER A, Rehbinder EM, Fardig M, Asad S, et al
    Filaggrin mutations in relation to skin barrier and atopic dermatitis in early infancy.
    Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20831.
    >> Share

  192. GUTERMUTH J, Pink AE, Worm M, Soldbro L, et al
    Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of cyclosporine A: a placebo-controlled, randomized, Phase 3 clinical trial (ECZTRA 7).
    Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20832.
    >> Share

  193. WOLLENBERG A, Beck LA, de Bruin Weller M, Simpson EL, et al
    Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials.
    Br J Dermatol. 2021 Oct 12. doi: 10.1111/bjd.20810.
    >> Share

  194. PUELLES J, Fofana F, Rodriguez D, Silverberg JI, et al
    Psychometric Validation and Responder Definition of Sleep Disturbance Numerical Rating Scale in Moderate-To-Severe Atopic Dermatitis.
    Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20783.
    >> Share

  195. BERMINGHAM WH, Ardern-Jones MR, Huissoon AP, Krishna MT, et al
    Forewarned is forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-CoV-2 vaccine uptake and global public health.
    Br J Dermatol. 2021;185:838-839.
    >> Share

  196. FLORES C
    Decoding the pharmacogenetics of nonsteroidal anti-inflammatory drug hypersensitivity.
    Br J Dermatol. 2021;185:697-698.
    >> Share

  197. STANDL M
    Addressing the causality of the association of atopic dermatitis with depression and anxiety using Mendelian randomization.
    Br J Dermatol. 2021;185:694-695.
    >> Share

  198. JURADO-ESCOBAR R, Dona I, Perkins JR, Laguna JJ, et al
    Polymorphisms in eicosanoid-related biosynthesis enzymes associated with acute urticaria/angioedema induced by nonsteroidal anti-inflammatory drug hypersensitivity.
    Br J Dermatol. 2021;185:815-824.
    >> Share

  199. BAURECHT H, Welker C, Baumeister SE, Weidnger S, et al
    Relationship between atopic dermatitis, depression and anxiety: a two-sample Mendelian randomization study.
    Br J Dermatol. 2021;185:781-786.
    >> Share

    September 2021
  200. NAKAMURA T, Haider S, Fontanella S, Murray CS, et al
    Modelling trajectories of parentally reported and physician-confirmed atopic dermatitis in a birth cohort study.
    Br J Dermatol. 2021 Sep 26. doi: 10.1111/bjd.20767.
    >> Share

  201. FORSYTH JR, Russell E, McPherson T
    A retrospective case series of paediatric Stevens-Johnson syndrome and toxic epidermal necrolysis: evaluation of practice using the British Association of Dermatology's National Guidelines for children and young people.
    Br J Dermatol. 2021 Sep 4. doi: 10.1111/bjd.20741.
    >> Share

    August 2021
  202. JACOBY TV, Chang MS, Thompson LL, Foreman RK, et al
    Histopathologically-confirmed lichenoid eruptions from immune checkpoint inhibitor therapy: A retrospective cohort analysis.
    Br J Dermatol. 2021 Aug 10. doi: 10.1111/bjd.20698.
    >> Share

    March 2021
  203. SCHONMANN Y, Mansfield KE, Mulick A, Roberts A, et al
    Inflammatory Skin Diseases and the Risk of Chronic Kidney Disease - Population-Based Case-control and Cohort analyses.
    Br J Dermatol. 2021 Mar 17. doi: 10.1111/bjd.20067.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016